Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 15/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12340801 | 0.87 | PSMB5 (0.47) | PSMB5PSMB8PSMB1 | |
| SCHEMBL12340799 | 0.87 | DPP4 (0.57) | PSMB5PSMB8ANPEPDPP4PSMB1 | |
| SCHEMBL12340805 | 0.80 | PSMB5 (0.57) | PSMB5PSMB8PSMB1 | |
| SCHEMBL12340810 | 0.76 | PSMB5 (0.44) | PSMB5PSMB8ANPEPDPP4PSMB1 | |
| SCHEMBL12340797 | 0.72 | DPP8 (0.62) | PSMB5PSMB8DPP4PSMB1 | |
| SCHEMBL10952773 | 0.68 | PSMB5 (0.56) | PSMB5PSMB8PSMB1 | |
| SCHEMBL12340807 | 0.68 | PSMB5 (0.60) | PSMB5PSMB8PSMB1 | |
| SCHEMBL21558113 | 0.67 | PSMB5 (0.54) | PSMB5PSMB8PSMB1 | |
| SCHEMBL13268236 | 0.66 | PSMB5 (0.67) | PSMB5PSMB8PSMB1 | |
| SCHEMBL26257809 | 0.66 | PSMB5 (0.44) | PSMB5PSMB8ANPEPPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250237-A1 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | BACH BIOSCIENCES, LLC | 2016-09-01 | — | — | US | disclosed |
| US-8563533-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150292-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | PREP, DPP4, PEPD | PSMB5 142/4885PSMB8 195/4885ANPEP 15/4885 |
| US-20160250237-A1 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | PREP, DPP4, PEPD | PSMB5 142/4885PSMB8 195/4885ANPEP 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.